Page last updated: 2024-10-28

hexamethonium and Brugada Syndrome

hexamethonium has been researched along with Brugada Syndrome in 1 studies

Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.

Brugada Syndrome: An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK; high risk of VENTRICULAR TACHYCARDIA; or VENTRICULAR FIBRILLATION; SYNCOPAL EPISODE; and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
OHYAMA, Y1
AOKI, Y1
TAMURA, K1
KAWABE, A1
IMAI, T1
KIKUTA, R1
EGUCHI, A1
MASHIMA, T1
OGURO, C1

Other Studies

1 other study available for hexamethonium and Brugada Syndrome

ArticleYear
A CASE OF ACUTE MYOCARDIAL INFARCTION WITH INITIAL ST SEGMENT DEPRESSIN.
    Japanese circulation journal, 1964, Volume: 28

    Topics: Abscess; Alanine Transaminase; Anal Canal; Arrhythmias, Cardiac; Aspartate Aminotransferases; Blood

1964